scholarly journals iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes

Biomaterials ◽  
2016 ◽  
Vol 104 ◽  
pp. 247-257 ◽  
Author(s):  
Lorena Simón-Gracia ◽  
Hedi Hunt ◽  
Pablo Scodeller ◽  
Jens Gaitzsch ◽  
Venkata Ramana Kotamraju ◽  
...  
Keyword(s):  
Peptide Conjugation ◽  
Tumor Delivery

scholarly journals Folic Acid-Targeted Paclitaxel-Polymer Conjugates Exert Selective Cytotoxicity and Modulate Invasiveness of Colon Cancer Cells

Pharmaceutics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 929
Author(s):  
Antonella Grigoletto ◽  
Gabriele Martinez ◽  
Daniela Gabbia ◽  
Tommaso Tedeschini ◽  
Michela Scaffidi ◽  
...  
Keyword(s):  
Folic Acid ◽  
Cancer Cells ◽  
Pharmacokinetic Profile ◽  
Strong Impact ◽  
Passive Targeting ◽  
Drug Conjugates ◽  
Tumor Delivery ◽  
The Right ◽  
Polymer Drug Conjugates ◽  
Ht 29

Although selective tumor delivery of anticancer drugs has been sought by exploiting either passive targeting or by ligand-mediated targeting, a selective anticancer therapy remains an unmet medical need. Despite the advances which have been achieved by nanomedicines, nanosystems such as polymer-drug conjugates still miss the goal of clinical efficacy. In this study, we demonstrated that polymer-drug conjugates require a thoroughly chemical design and the right targeting agent/polymer ratio to be selective and effective towards cancer cells. In particular, two PEG conjugates carrying paclitaxel and targeted with different folic acid (FA)/PEG ratios (one or three) were investigated. The cytotoxicity study in positive (HT-29) and negative (HCT-15) FA receptor (FR)-cell lines demonstrated that the conjugates with one or three FAs were 4- or 28-fold more active in HT-29 cells, respectively. The higher activity of the 3-FA conjugate was confirmed by its strong impact on cell cycle arrest. Furthermore, FA targeting had a clear effect on migration and invasiveness of HT-29 cells, which were significantly reduced by both conjugates. Interestingly, the 3-FA conjugate showed also an improved pharmacokinetic profile in mice. The results of this study indicate that thorough investigations are needed to optimize and tune drug delivery and achieve the desired selectivity and activity towards cancer cells.

scholarly journals Nanoparticles as Drug Delivery Systems of RNAi in Cancer Therapy

Molecules ◽  
2021 ◽  
Vol 26 (8) ◽  
pp. 2380
Author(s):  
Diedie Li ◽  
Chengzhi Gao ◽  
Meiyan Kuang ◽  
Minhao Xu ◽  
Ben Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Therapeutic Strategy ◽  
Target Gene ◽  
Treatment Approach ◽  
Systemic Delivery ◽  
Efficient Delivery ◽  
Rnai Therapeutics ◽  
Cellular Machinery ◽  
Tumor Delivery

RNA interference (RNAi) can mediate gene-silencing by knocking down the expression of a target gene via cellular machinery with much higher efficiency in contrast to other antisense-based approaches which represents an emerging therapeutic strategy for combating cancer. Distinct characters of nanoparticles, such as distinctive size, are fundamental for the efficient delivery of RNAi therapeutics, allowing for higher targeting and safety. In this review, we present the mechanism of RNAi and briefly describe the hurdles and concerns of RNAi as a cancer treatment approach in systemic delivery. Furthermore, the current nanovectors for effective tumor delivery of RNAi therapeutics are classified, and the characteristics of different nanocarriers are summarized.

scholarly journals Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell–selectin interaction kinetics

Biomaterials ◽  
2012 ◽  
Vol 33 (20) ◽  
pp. 5004-5012 ◽  
Author(s):  
Hao Cheng ◽  
Marta Byrska-Bishop ◽  
Cathy T. Zhang ◽  
Christian J. Kastrup ◽  
Nathaniel S. Hwang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Membrane ◽  
Cell Rolling ◽  
Peptide Conjugation ◽  
Interaction Kinetics ◽  
Membrane Engineering

pH-Triggered Micelles for Tumor Delivery

2011 ◽  
pp. 1099-1131
Author(s):  
Haiqing Yin ◽  
You Han Bae
Keyword(s):  
Tumor Delivery

Stabilization of hyaluronan-based materials by peptide conjugation and its use as a cell-seeded scaffold in tissue engineering

2018 ◽  
Vol 201 ◽  
pp. 300-307 ◽  
Author(s):  
Sergej Karel ◽  
Jana Sogorkova ◽  
Martina Hermannova ◽  
Kristina Nesporova ◽  
Lucie Marholdova ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Peptide Conjugation ◽  
A Cell

scholarly journals Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients

Antibodies ◽  
2019 ◽  
Vol 8 (1) ◽  
pp. 3 ◽  
Author(s):  
Andrew T. Lucas ◽  
Ryan Robinson ◽  
Allison N. Schorzman ◽  
Joseph A. Piscitelli ◽  
Juan F. Razo ◽  
...  
Keyword(s):  
Cytotoxic Agents ◽  
Clinical Use ◽  
Individual Agent ◽  
Antibody Drug Conjugates ◽  
Drug Conjugates ◽  
Rational Development ◽  
Patient Variables ◽  
Tumor Delivery ◽  
Agent Characteristics ◽  
Antibody Drug

The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution. This review provides an updated summary of factors known to affect the disposition of mAbs/ADCs in development and in clinical use, as well as how these factors should be considered in the selection and design of preclinical studies of ADC agents in development.

scholarly journals Accelerated mineralization on nanofibers via non-thermal atmospheric plasma assisted glutamic acid templated peptide conjugation

2019 ◽  
Vol 6 (4) ◽  
pp. 231-240 ◽  
Author(s):  
Günnur Onak ◽  
Ozan Karaman
Keyword(s):  
Surface Modification ◽  
Glutamic Acid ◽  
Fluorescent Microscopy ◽  
Cellular Adhesion ◽  
Atmospheric Plasma ◽  
Peptide Conjugation ◽  
Carboxylic Groups ◽  
Modification Technique ◽  
Simulated Body Fluids ◽  
Effect Of Surface

Abstract Surface modification by non-thermal atmospheric plasma (NTAP) treatment can produce significantly higher carboxylic groups on the nanofibers (NF) surface, which potentially can increase biomineralization of NF via promoting glutamic acid (GLU) templated peptide conjugation. Herein, electrospun poly(lactide-co-glycolide) (PLGA) scaffolds were treated with NTAP and conjugated with GLU peptide followed by incubation in simulated body fluids for mineralization. The effect of NTAP treatment and GLU peptide conjugation on mineralization, surface wettability and roughness were investigated. The results showed that NTAP treatment significantly increased GLU peptide conjugation which consequently enhanced mineralization and mechanical properties of NTAP treated and peptide conjugated NF (GLU-pNF) compared to neat PLGA NF, NTAP treated NF (pNF) and GLU peptide conjugated NF (GLU-NF). The effect of surface modification on human bone marrow derived mesenchymal stem cells adhesion, proliferation and morphology was evaluated by cell proliferation assay and fluorescent microscopy. Results demonstrated that cellular adhesion and proliferation were significantly higher on GLU-pNF compared to NF, pNF and GLU-NF. In summary, NTAP treatment could be a promising modification technique to induce biomimetic peptide conjugation and biomineralization for bone tissue engineering applications.

Sign in / Sign up

Export Citation Format

Share Document